Damora Therapeutics (DMRA) Net Cash Flow Growth (1y) (2020 - 2026)
Damora Therapeutics (DMRA) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | 53.46% |
| 10 | Damora Therapeutics | 1.01 Bn | 803.94 Mn | - | 11,388.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11,388.36% |
| Dec 31, 2025 | 112.24% |
| Sep 30, 2025 | 29.08% |
| Jun 30, 2025 | -217.74% |
| Mar 31, 2025 | -875.60% |
| Dec 31, 2024 | -160.22% |
| Sep 30, 2024 | -19,573.68% |
| Jun 30, 2024 | 190.78% |
| Mar 31, 2024 | 96.77% |
| Dec 31, 2023 | -163.90% |
| Sep 30, 2023 | 101.71% |
| Jun 30, 2023 | 85.94% |
| Mar 31, 2023 | 54.50% |
| Dec 31, 2022 | 186.25% |
| Sep 30, 2022 | 47.40% |
| Jun 30, 2022 | -146.34% |
| Mar 31, 2022 | 80.85% |
| Dec 31, 2021 | -104.42% |
| Sep 30, 2021 | -104.46% |
| Jun 30, 2021 | 15.22% |